comprehensive -WSS

comprehensive

author：leisure time 2025-09-29 01:46:23 - browse：47

The Food and Drug Administration on Tuesday approved brexanolone, the first drug specifically targeted to treat postpartum depression — the most common complication of childbirth. Yet it’s a condition that often goes untreated because new mothers fear being stigmatized if they report symptoms.

Brexanolone is the first drug developed by and approved from Sage Therapeutics. The Cambridge, Mass.-based biotech company will market the new medicine under the brand name Zulresso.

“This approval is important for postpartum depression patients and it’s important for our company. It’s rare in your career when you can introduce a new medicine that is different from what’s out there,” said Sage CEO Jeff Jonas.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Gut bacteria may contribute to kidney autoimmunity, study finds

explore

WSS

In search for therapies for solid tumors, companies turn to claudin

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

Insurer loopholes limit power of law against surprise medical bills

Medicare Advantage 2025 payments will dip, Biden administration says

Medicare Advantage 2025 payments will dip, Biden administration says

Gut bacteria may contribute to kidney autoimmunity, study finds

entertainment

comprehensive

leisure time

At least 13 dead in Texas as scorching temps continue

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

Wildfire smoke exposes gaps in outdoor worker protections

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

Activists slam private health insurers over coverage restrictions

Bird flu reported in person exposed to presumably infected cattle

United colonoscopy coverage change 'may cost lives,' doctors say

Biotech companies concerned about China biosecurity crackdown

DIEP, the 'gold standard' of breast reconstruction, is under threat

FogPharma raises $145 million in rare Series E round

entertainment

Flu vaccine offering decent levels of protection this winter, new data show

Pfizer highlights cancer drugs it thinks could reignite investor interest

Covid silver lining: Unprecedented look at human immune system

Congress gives doctors Medicare pay bump

Scientists unlock the key to scar

Gut bacteria may contribute to kidney autoimmunity, study finds

leisure time

entertainment

explore

focus